Author Affiliation: Department of Medicine, University of California, San Francisco.
I agree with Dr Dean's statement that the “application of therapy should be based on the evidence.” That is why it is disappointing that he refers to the “life-saving properties” of DESs without offering support for this statement. Indeed, significant mortality benefits have not been seen with DESs.1 The end point used in almost all large, high-quality randomized controlled trials on this subject is a composite outcome, largely driven by decreased need for revascularization.
Redberg RF. Cardiovascular Device Technology and Health Care Cost—Reply. Arch Intern Med. 2011;171(18):1689. doi:10.1001/archinternmed.2011.465